<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00295789</url>
  </required_header>
  <id_info>
    <org_study_id>JCOG0505</org_study_id>
    <secondary_id>C000000335</secondary_id>
    <nct_id>NCT00295789</nct_id>
  </id_info>
  <brief_title>Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)</brief_title>
  <official_title>A Randomized Phase III Trial of Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Carboplatin in Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haruhiko Fukuda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Clinical Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical benefits of Paclitaxel plus Carboplatin compared with Paclitaxel
      plus Cisplatin in Stage IVb, Persistent, or Recurrent Cervical Cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prognosis of the advanced, recurrent, or persistent cervical cancer, which is not amenable to
      curative treatment with surgery and/or radiation therapy, still remains poor. Recently,
      cisplatin plus paclitaxel for palliative chemotherapy were reported to improve the response
      rate and progression-free interval compared to cisplatin alone and has been shown as a new
      appropriate regimen. However, more effective and/or less toxic combinations are needed.
      Carboplatin as a single agent has less response rate but less overall toxicity than
      cisplatin. Particularly, because less nephrotoxicity does not require hydration and less
      neurotoxicity enables 3hrs administration of paclitaxel in the combination, out patient
      therapy becomes possible and patients' quality of life must improve. Therefore, we planned to
      evaluate the benefits of less toxicity of the chemotherapy containing paclitaxel and
      carboplatin, which could reduce the hospitalised days, in comparison with the standard
      chemotherapy containing paclitaxel and cisplatin. This clinical trial is targeted on the
      patients in Japan with incurable cervical cancer diagnosed by means of image.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>During the study conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severe adverse events</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of periods of non-hospitalization to those of the planned treatment</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">253</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: chemotherapy: Paclitaxel/Cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: chemotherapy: Paclitaxel/Carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy: Paclitaxel/Cisplatin</intervention_name>
    <description>Drug: chemotherapy: Paclitaxel/Cisplatin</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy: Paclitaxel/Carboplatin</intervention_name>
    <description>Drug: chemotherapy: Paclitaxel/Carboplatin</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. histologically proven uterine cervical cancer

          2. squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the
             uterine cervix

          3. one of the followings, 1)primary stage Ⅳb cervical cancer, 2)the first relapse or
             persistent cervical cancer after curative first line treatments, 3)the second relapse
             or persistent cervical cancer after curative second line treatments including
             radiation, systemic chemotherapy, hormonal therapy, or vaccination therapy for the
             first relapse

          4. Patients may have been previously treated with less than 50 Gy of palliative radiation
             therapy

          5. Patients have received no prior treatment or a certain interval must have elapsed from
             the last administration of previous treatments including palliative radiation therapy

          6. one of the followings, 1)There is at least one metastatic lesion outside the pelvic
             cavity except paraaortic LN and/or inguinal LN, 2)There is no metastatic lesion
             outside the pelvic cavity except paraaortic LN and/or inguinal LN and some of the
             lesions have been irradiated, 3)All lesions are localized inside the pelvic cavity,
             and some of them have been irradiated

          7. no prior surgical therapy for metastatic lesions of the lung or inside the pelvic
             cavity

          8. no bilateral hydronephrosis

          9. no prior chemotherapy including more than two platinum-containing regimens

         10. no prior chemotherapy including taxane

         11. age: 20 to75 years

         12. PS: 0-2

         13. ANC ≧1,500 /mm3, Plt≧10.0×104/mm3, T-bil≦1.5 mg/dl, GOT（AST）≦100IU/l, sCre ≦1.2 mg/dl,
             Ccr≧50ml/min in using the Cockcroft-Gault equation, and normal ECG

         14. written informed consent

        Exclusion Criteria:

          1. patients who have some neurologically functional disorder

          2. symptomatic CNS metastasis

          3. hypersensitive to alcohol

          4. active infection

          5. HBs antigen positive

          6. uncontrollable hypertension

          7. history of myocardiac infarction within six months

          8. unstable angina

          9. uncontrollable diabetes

         10. Patients with a concomitant or prior invasive malignancy (except intramucosal
             malignancy which are curable with local therapy) who have had any evidence of the
             disease within the last 5 years

         11. women during pregnancy or breast-feeding

         12. patients with psychiatric illness

         13. patients who have been treated with the systemic steroids medication
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshiharu Kamura, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kurume University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya,Chikusa-ku,Kanokoden,1-1</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya Medical Center</name>
      <address>
        <city>Nagoya,Naka-ku,Sannomaru,4-1-1</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center</name>
      <address>
        <city>Matsuyama,Horinouchi,13</city>
        <state>Ehime</state>
        <zip>790-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka,Higashi-ku,Maidashi,3-1-1</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka,Minami-ku,Notame,3-1-1</city>
        <state>Fukuoka</state>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University School of Medicine</name>
      <address>
        <city>Kurume, Asahi-machi, 67</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma Prefectural Cancer Center</name>
      <address>
        <city>Ota,Takabayashi-nishi-cho,617-1</city>
        <state>Gunma</state>
        <zip>373-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kure Medical Center Chugoku Cancer Center</name>
      <address>
        <city>Kure,Aoyama-cho,3-1</city>
        <state>Hiroshima</state>
        <zip>737-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>North-14 West-5 Kita-ku,Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Medical University</name>
      <address>
        <city>S-1,W-16,Chuo-ku,Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Medical Center for Adults</name>
      <address>
        <city>Akashi,Kitaouji-cho,13-70</city>
        <state>Hyogo</state>
        <zip>673-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Clinical Medicine,Tsukuba University Hospital</name>
      <address>
        <city>Tsukuba,Tennodai,1-1-1</city>
        <state>Ibaraki</state>
        <zip>305-8575</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagoshima City Hospital</name>
      <address>
        <city>Kagoshima,Kajiya-cho,20-17</city>
        <state>Kagoshima</state>
        <zip>892-8580</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai,Aoba-ku,Seiryo-machi,1-1</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinshu University</name>
      <address>
        <city>Matsumoto,Asahi,3-1-1</city>
        <state>Nagano</state>
        <zip>390-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagaoka Red Cross Hospital</name>
      <address>
        <city>Nagaoka,Terashima-cho,297-1</city>
        <state>Niigata</state>
        <zip>940-2085</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital</name>
      <address>
        <city>Niigata,Kawagishi-cho,2-15-3</city>
        <state>Niigata</state>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Medical Center for Cancer and Cardiovascular Diseases</name>
      <address>
        <city>Osaka,Higashinari-ku,Nakamichi,1-3-3</city>
        <state>Osaka</state>
        <zip>537-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City General Hospital</name>
      <address>
        <city>Osaka,Miyakojima-ku,Miyakojimahondori,2-13-22</city>
        <state>Osaka</state>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki University School of Medicine</name>
      <address>
        <city>Osaka-Sayama,Ohno-higashi,377-2</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine, Saga University</name>
      <address>
        <city>Saga,Nabeshima,5-1-1</city>
        <state>Saga</state>
        <zip>849-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical Center, Saitama Medical School</name>
      <address>
        <city>Kawagoe,Komoda,1981</city>
        <state>Saitama</state>
        <zip>350-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center</name>
      <address>
        <city>Kita-adachi,Ina,Komuro,818</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Defense Medical College</name>
      <address>
        <city>Tokorozawa,Namiki,3-2</city>
        <state>Saitama</state>
        <zip>359-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University School of Medicine</name>
      <address>
        <city>Bunkyo-ku,Hongo,3-1-3</city>
        <state>Tokyo</state>
        <zip>113-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Bunkyo-ku,Hongo,7-3-1</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku,Tsukiji,5-1-1</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute Hospital</name>
      <address>
        <city>Koto-ku,Ariake,3-10-6</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jikei University Hospital</name>
      <address>
        <city>Minato-ku,Nishishinbashi,3-25-8</city>
        <state>Tokyo</state>
        <zip>105-8461</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tottori University School of Medicine</name>
      <address>
        <city>Yonago,Nishimachi,36-1</city>
        <state>Tottori</state>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.jcog.jp/</url>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2006</study_first_submitted>
  <study_first_submitted_qc>February 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2006</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Japan Clinical Oncology Group</investigator_affiliation>
    <investigator_full_name>Haruhiko Fukuda</investigator_full_name>
    <investigator_title>JCOG Data Center</investigator_title>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>palliative chemotherapy</keyword>
  <keyword>recurrent</keyword>
  <keyword>persistent</keyword>
  <keyword>stageⅣb</keyword>
  <keyword>cisplatin</keyword>
  <keyword>carboplatin</keyword>
  <keyword>paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

